Posts by: Alice Melão

News

The U.S. Food and Drug Administration (FDA) has suspended two Phase 1 trials assessing Cellectis’ CAR T-cell therapy UCART123 in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN) after the first ... Read more

August 24, 2017August 24, 2017

Aptevo, Alligator Biosciences to Produce Bispecific Antibody ALG.APV-527 for Future Clinical Trials

News

Aptevo Therapeutics and Alligator Bioscience will jointly manufacture their immunotherapy candidate ALG.APV-527 in order to fulfill the requiremeents of an investigational new drug (IND) application for future human clinical testing. ALG.APV-527, developed using Seattle-based Aptevo’s ... Read more

August 23, 2017

Combination of Pexa-Vec, Checkpoint Inhibitors to Be Tested in Advanced Colon Cancer Trial

News

SillaJen and the National Cancer Institute (NCI) are partnering to test Pexa-Vec in combination with specific checkpoint inhibitors for the treatment of patients with advanced stage colorectal cancer (CRC). The cooperative research and development agreement (CRADA) ... Read more

August 22, 2017

FDA Accepts Investigational New Drug Application for VBI’s Therapy to Treat Brain Cancer

News

The U.S. Food and Drug Administration has accepted VBI Vaccines‘ investigational new drug (IND) application for its immunotherapy VBI-1901, which targets the most common and aggressive form of malignant brain cancer, glioblastoma multiforme ... Read more

August 1, 2017

Natural Killer Cells Are Important to Ceplene’s Ability to Keep Leukemia in Remission, Trial Shows

News

An immune system component known as natural killer cells is crucial for a combination of Ceplene and interleukin-2 to keep acute myeloid leukemia in remission, according to a Phase 4 clinical trial. ... Read more

July 20, 2017

NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows

News

Adding TyrNovo‘s NT-219 to Merck’s Keytruda (pembrolizumab) converted Keytruda-resistant tumors into therapy responders, stopping tumor progression, a study reports. The research, which involved a number of cancers, was a collaboration between Bar Ilan University and Rabin ... Read more

July 19, 2017

Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows

News

The immunotherapy Opdivo (nivolumab) is less aggressive than standard-of-care chemotherapy for patients with recurrent or metastatic head and neck cancer, and has less of an impact on patients’ quality of ... Read more

July 17, 2017

Phase 3 Trial to Assess Cabometyx Combo Therapies vs. Sutent in Advanced Kidney Cancer Patients

News

Exelixis and Bristol-Myers Squibb are starting a Phase 3 trial called CheckMate 9ER to assess Cabometyx (cabozantinib) in combination with immune checkpoint inhibitors in patients with newly-diagnosed advanced renal cell carcinoma, the ... Read more

June 22, 2017June 22, 2017

Generon’s A-337 Antibody Is Entering Phase 1 Trial as Treatment for Solid Tumors

News

The A-337 antibody that Generon Corporation developed to sic immune-system T-cells on cancer cells that express the surface protein EpCAM will be tested in a Phase 1 clinical trial in Australia. The ... Read more

June 21, 2017

Acceleron Discontinues Development of Dalantercept for Advanced Renal Cell Carcinoma Therapy

News

The DART Phase 2 clinical trial, assessing Acceleron Pharma’s dalantercept in combination with Pfizer’s Inlyta (axitinib) in advanced renal cell carcinoma (RCC) patients, has failed to demonstrate an improvement in patients’ time ... Read more